10x Genomics TXG
10x Genomics, Inc. · Nasdaq · Laboratory Analytical Instruments
$81.55-2.48%close on Oct. 29, 2026 · volume 1.8M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 22, 2026 | Shehnaaz Suliman director | Sold 10b5-1 plan | 5,723 | $81.19 $78.20-$82.28 | $464,668 |
| Sept. 22, 2026 | Serge Saxonov Chief Executive Officer, director | Sold 10b5-1 plan | 25,000 | $81.22 $78.23-$82.37 | $2.03 million |
| Sept. 9, 2026 | Adam Taich Chief Financial Officer | Sold 10b5-1 plan | 46,388 | $64.57 $63.68-$65.26 | $3.00 million |
| Sept. 3, 2026 | John R. Stuelpnagel director | Sold | 20,000 | $61.75 $60.66-$62.61 | $1.24 million |
| Aug. 26, 2026 | Serge Saxonov Chief Executive Officer, director | Sold 10b5-1 plan | 10,486 | $63.69 $63.02-$64.75 | $667,901 |
| Aug. 24, 2026 | Serge Saxonov Chief Executive Officer, director | Sold | 18,545 | $63.02 | $1.17 million |
| Aug. 24, 2026 | Adam Taich Chief Financial Officer | Sold | 17,166 | $63.02 | $1.08 million |
| Aug. 24, 2026 | Benjamin J. Hindson See Remarks, director | Sold | 13,818 | $63.02 | $870,860 |
| Aug. 24, 2026 | Shehnaaz Suliman director | Sold 10b5-1 plan | 2,207 | $63.65 $62.73-$63.97 | $140,478 |
| Aug. 14, 2026 | Sarah A. Teichmann director | Sold 10b5-1 plan | 2,273 | $57.15 | $129,902 |
| Aug. 13, 2026 | Sarah A. Teichmann director | Sold 10b5-1 plan | 5,278 | $57.29 | $302,377 |
| Aug. 11, 2026 | John R. Stuelpnagel director | Sold | 20,000 | $57.75 $57.58-$58.73 | $1.16 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.